首页> 外文期刊>Pharmaceutical research >Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-I in Human Breast Cancer
【24h】

Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-I in Human Breast Cancer

机译:对人乳腺癌抗癌肽,乳房肽的双特异性复合物和药物缀合物的设计与体外评价

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose LyP-1, a nine-amino-acid tumor homing peptide, selectively binds to its cognate receptor, p32. Overexpression of p32 in certain tumors should allow use of LyP-1 as a targeting agent for the delivery of therapeutic or diagnostic agents. Peptide conjugates are developed for enhanced pretargeting of MDA-MB-231 breast cancer cells with peptideantibody bispecific complexes and targeting with multipledrug/- fluorophore-conjugated nano-polymers.
机译:目的型乳清氧酸肿瘤杂化肽,选择性地结合其同源受体P32。 某些肿瘤中P32的过度表达应允许使用乳乳型1作为递送治疗剂或诊断剂的靶向剂。 肽缀合物的开发用于增强MDA-MB-231乳腺癌细胞的预靶向肽类化合物双特异性络合物,并靶向uperPledrug / - 荧光团 - 缀合的纳米聚合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号